Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec;21(6):e768-74.
doi: 10.3747/co.21.2125.

Using pet-ct to reduce futile thoracotomy rates in non-small-cell lung cancer: a population-based review

Affiliations

Using pet-ct to reduce futile thoracotomy rates in non-small-cell lung cancer: a population-based review

M Smoragiewicz et al. Curr Oncol. 2014 Dec.

Abstract

Background: Combined positron-emission tomography and computed tomography (pet-ct) reduces futile thoracotomy (ft) rates in patients with non-small-cell lung cancer (nsclc). We sought to identify preoperative risk factors for ft in patients staged with pet-ct.

Methods: We retrospectively reviewed all patients referred to the BC Cancer Agency during 2009-2010 who underwent pet-ct and thoracotomy for nsclc. Patients with clinical N2 disease were excluded. An ft was defined as any of a benign lesion; an exploratory thoracotomy; pathologic N2 or N3, stage iiib or iv, or inoperable T3 or T4 disease; and recurrence or death within 1 year of surgery.

Results: Of the 108 patients who met the inclusion criteria, ft occurred in 27. The main reason for ft was recurrence within 1 year (14 patients) and pathologic N2 disease (10 patients). On multivariate analysis, an Eastern Cooperative Oncology Group performance status greater than 1, a pet-ct positive N1 status, a primary tumour larger than 3 cm, and a period of more than 16 weeks from pet-ct to surgery were associated with ft. N2 disease that had been negative on pet-ct occurred in 21% of patients with a pet-ct positive N1 status and in 20% of patients with tumours larger than 3 cm and non-biopsy mediastinal staging only. The combination of pet-ct positive N1 status and a primary larger than 3 cm had 85% specificity, and the presence of either risk factor had 100% sensitivity, for ft attributable to N2 disease.

Conclusions: To reduce ft attributable to N2 disease, tissue biopsy for mediastinal staging should be considered for patients with pet-ct positive N1 status and with tumours larger than 3 cm even with a pet-ct negative mediastinum.

Keywords: Non-small-cell lung cancer; endobronchial ultrasonography; endoscopic ultrasonography; lymphatic metastasis or pathology; mediastinal staging; mediastinoscopy; positron-emission tomography–computed tomography; thoracotomy.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107. - DOI - PubMed
    1. Socinski MA, Crowell R, Hensing TE, et al. on behalf of the American College of Chest Physicians. Treatment of non-small cell lung cancer, stage iv: accp evidence-based clinical practice guidelines (2nd edition) Chest. 2007;132(suppl):277S–89S. doi: 10.1378/chest.07-1381. - DOI - PubMed
    1. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K, on behalf of the American College of Chest Physicians Treatment of non-small cell lung cancer stage i and stage ii: accp evidence-based clinical practice guidelines (2nd edition) Chest. 2007;132(suppl):234S–42S. doi: 10.1378/chest.07-1378. - DOI - PubMed
    1. Robinson LA, Ruckdeschel JC, Wagner H, Jr, Stevens CW, on behalf of the American College of Chest Physicians Treatment of non-small cell lung cancer-stage iiia: accp evidence-based clinical practice guidelines (2nd edition) Chest. 2007;132(suppl):243S–65S. doi: 10.1378/chest.07-1379. - DOI - PubMed
    1. Jett JR, Schild SE, Keith RL, Kesler KA, on behalf of the American College of Chest Physicians Treatment of non-small cell lung cancer, stage iiib: accp evidence-based clinical practice guidelines (2nd edition) Chest. 2007;132(suppl):266S–76S. doi: 10.1378/chest.07-1380. - DOI - PubMed

LinkOut - more resources